DAXOR CORPORATION - CLOSED END FUND

9,2842

22-ноября-24 15:44:58

15 мин. задержка

Акции

+0,3542

+3,97%

Сегодняшний диапазон

9,0000 - 9,3100

ISIN

N/A

Источник

NASDAQ

DAXOR'S INNOVATIVE BVA-100™ BLOOD VOLUME DIAGNOSTIC FEATURED AT MEDAXIOM CV TRANSFORUM FALL '24

09 окт 2024 07:00:00 Источник Nasdaq GlobeNewswire
Daxor Corporation to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

08 окт 2024 07:00:00 Источник Nasdaq GlobeNewswire
Daxor Corporation Streamlines Regulatory Strategy for Groundbreaking Diagnostic Device

27 сен 2024 16:00:00 Источник Nasdaq GlobeNewswire
Daxor Corporation to Exhibit at the Heart Failure Society of America Annual Scientific Meeting 2024

19 сен 2024 07:00:00 Источник Nasdaq GlobeNewswire
Newly Published Review Highlights the Pivotal Role of Daxor’s Blood Volume Analysis Technology in Advancing Cardiorenal Syndrome Management

12 сен 2024 07:00:00 Источник Nasdaq GlobeNewswire
Daxor Corporation Receives $300K Matching Fund Award From Launch Tennessee

05 сен 2024 07:00:00 Источник Nasdaq GlobeNewswire
Leading Central Florida Hospital Implements Daxor’s BVA-100™ Blood Volume Diagnostic for Heart Failure Patient Care

04 сен 2024 07:30:00 Источник Nasdaq GlobeNewswire
Daxor Corporation CEO and President Michael Feldschuh Delivers Corporate Update in Shareholder Letter

03 сен 2024 15:05:00 Источник Nasdaq GlobeNewswire
Daxor Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference

03 сен 2024 11:15:00 Источник Nasdaq GlobeNewswire
Daxor Corporation Announces Launch of BVA Program at Mid-South Largest Integrated Network

29 авг 2024 07:00:00 Источник Nasdaq GlobeNewswire
Daxor Corporation Awarded $1.9M Contract by The U.S. Air Force for Development of its Next Generation Tracer System in its Point-of-Care Blood Volume Analyzer

06 авг 2024 07:00:00 Источник Nasdaq GlobeNewswire
Daxor Expands To Three New Facilities As Blood Volume Analysis Technology Gains Momentum Nationwide

05 авг 2024 07:00:00 Источник Nasdaq GlobeNewswire
Daxor Corporation Awarded New U.S. Defense Health Agency Contract for Added Capabilities to Its Point-of-Care Blood Volume Analyzer

24 июл 2024 07:00:00 Источник Nasdaq GlobeNewswire
Daxor Corporation’s BVA-100™ Blood Volume Diagnostic Expands to Three New Centers, Gains Traction Nationwide

11 июл 2024 07:00:00 Источник Nasdaq GlobeNewswire
Daxor Corporation to Showcase the Benefits of BVA-100™ Guided-Care at the American Association of Heart Failure Nurses (AAHFN) 20th Annual Meeting

18 июн 2024 07:00:00 Источник Nasdaq GlobeNewswire
New Studies Prove the Clinical Benefits of Daxor’s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion

16 апр 2024 07:00:00 Источник Nasdaq GlobeNewswire
DAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE SPRING’24 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR’S BLOOD VOLUME DIAGNOSTIC (BVA-100™)

15 апр 2024 07:00:00 Источник Nasdaq GlobeNewswire
Daxor Corporation Announces New Hospital Account at Leading Chicago Hospital

10 апр 2024 07:00:00 Источник Nasdaq GlobeNewswire
Daxor Corporation to Exhibit at the American College of Cardiology for ACC.24

01 апр 2024 07:00:00 Источник Nasdaq GlobeNewswire
Daxor Corporation Acquires Volumex® and Megatope® From Its Existing Supplier Along With Glofil® to Enhance Existing Suite of Diagnostics

25 мар 2024 07:00:00 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.